XBiotech (XBIT) announced ending its Phase 3 clinical trial, XCITE, designed for assessing lead product candidate Xilonix for the treatment of colorectal cancer. The decision has been taken pursuant to a second planned analysis by the Independent Data Monitoring Committee which determined that it would be unlikely to show sufficient efficacy to continue.
Tesaro (TSRO) announced that it has suspended the patient recruitment in a Phase 2 clinical trial assessing niraparib for the treatment of prostate cancer being conducted by collaboration partner Janssen Biotech. The FDA approved niraparib in March for treating certain patients with epithelial, ovarian, fallopian tube or primary peritoneal cancer.
Lexicon Pharmaceuticals Inc. (LXRX) announced that its Phase 3 clinical trail, TANDEM 3 met its primary endpoint of demonstrating superiority over placebo as measured by the proportion of patients achieving HbA1C levels less than 7.0% at week 24.The study is designed to assess the efficacy of sotagliflozin for the treatment of type 1 diabetes. The results showed that there were no episodes of hypoglycemia or diabetic ketoacidosis after randomization. The company has an agreement with Sanofi, which gives the company global rights to the product, except for in Japan.
Lexicon stock is up 18 percent this year so far while its 12 years gain stands at 12 percent.